ArticleOncotarget2016
RAB22A overexpression promotes the tumor growth of melanoma.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Rab22a is a novel prognostic marker for cell progression in breast cancer.International journal of molecular medicine · 2020Trial
- Retraction: MicroRNA98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4.Oncotarget · 2026Article
- Retraction: MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1.Oncotarget · 2024Article
- Exosomal lncRNA LINC02191 Promotes Laryngeal Squamous cell Carcinoma Progression by Targeting miR-204-5p/RAB22A Axis and Regulating PI3K/Akt/mTOR Pathway.Biochemical genetics · 2024Article
- miR-204 suppresses uveal melanoma cell migration and invasion through negative regulation of RAB22A.Functional & integrative genomics · 2023Article
- The Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness.Frontiers in oncology · 2022Review
- LncRNA MCF2L-AS1 aggravates the malignant development of colorectal cancer via targeting miR-105-5p/RAB22A axis.BMC cancer · 2021Article
- MiR-520b inhibits proliferation, migration and invasion in gallbladder carcinoma by targeting RAB22A.Archives of medical science : AMS · 2021Article
- Long non-coding RNA PSMA3-AS1 enhances cell proliferation, migration and invasion by regulating miR-302a-3p/RAB22A in glioma.Bioscience reports · 2020Observational
- Subversion of Ras Small GTPases in Cutaneous Melanoma Aggressiveness.Frontiers in cell and developmental biology · 2020Review
- miRNA-520c-3p accelerates progression of nasopharyngeal carcinoma via targeting RAB22A.Oncology letters · 2020Article
- The Paradoxical Behavior of microRNA-211 in Melanomas and Other Human Cancers.Frontiers in oncology · 2020Review
- MicroRNA-193b acts as a tumor suppressor in colon cancer progression via targeting RAB22A.Experimental and therapeutic medicine · 2019Article
- Loss of SR-BI Down-Regulates MITF and Suppresses Extracellular Vesicle Release in Human Melanoma.International journal of molecular sciences · 2019Article
- Role of miR-520b in non-small cell lung cancer.Experimental and therapeutic medicine · 2018Article
- Article
- Consequences of Rab GTPase dysfunction in genetic or acquired human diseases.Small GTPases · 2018Review
- Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma.Journal of Cancer · 2017Article
Corrections and comments
- Retraction · 2025-05-19Euphemisms for Plagiarism · Investigation by Journal/Publisher · Plagiarism of Image ·
- Retracted
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant melanoma is the most aggressive type of skin cancer. RAB22A, a member of RAS oncogene family, has been found to be significantly upregulated in multiple human cancers. In the present study, we found that RAB22A mRNA expression was significantly upregulated in melanoma tissues (including 60 primary melanomas and 84 metastatic melanomas) compared to benign nevi (n = 20), which were significantly higher in metastatic melanoma tissues than primary tissues. Immunohistochemistry data further showed that the positive immunoreactivity of RAB22A was detected in 66% (95/144) melanoma tissues, but not in benign nevi. Moreover, high expression of RAB22A was significantly associated with advanced clinical stage in melanoma. Furthermore, patients with high RAB22A expression had shorter overall survival compared those with low expression of RAB22A. In-vitro study showed that RAB22A was also upregulated in melanoma cell lines WM35, A375, WM451, and SK-MEL-1, when compared with the normal melanocyte HM cells. Knockdown of RAB22A significantly reduced the proliferation, migration and invasion of melanoma A375 cells, while overexpression of RAB22A significantly promoted these malignant phenotypes. In addition, RAB22A was found to be a target of miR-203, a tumor suppressive miRNA in melanoma. Besides, miR-203 was downregulated in melanoma tissues and cell lines, when compared with benign nevi and HM cells, respectively. Taken these findings together, our study could validate an oncogenic role of RAB22A in melanoma, suggesting that RAB22A may be a potential therapeutic target for melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.